{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-024726","form_type":"8-K","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2023-07-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.028479+00:00","generated_at":"2026-06-13T07:27:03.333607+00:00","sec_items":["4.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Elite Pharmaceuticals dismisses Buchbinder, appoints Mazers as new auditor","bullets":["Audit Committee approved appointment of Mazers USA LLP on July 11, 2023, effective same day.","Buchbinder Tunick & Company LLP was dismissed as independent auditor, effective July 12, 2023.","No disagreements or reportable events with Buchbinder during fiscal years 2022 and 2023 or subsequent interim period.","Buchbinder's reports for those fiscal years contained no adverse opinion or qualification."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-024726","json":"https://secwatch.observer/filing/0001493152-23-024726.json","markdown":"https://secwatch.observer/filing/0001493152-23-024726.md","text":"https://secwatch.observer/filing/0001493152-23-024726.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315223024726/0001493152-23-024726-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315223024726/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T07:27:03.333607+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1abb9d034a40830b099d36c95567bc08d5a74311","claim":"ELITE PHARMACEUTICALS INC /NV/ engaged Mazers USA LLP as its auditor.","evidence_excerpt":"Company”) approved the appointment, effective July 11, 2023, of Mazers USA LLP (“Mazers”) as the Company’s new independent registered public accounting firm to audit the Company’s consolidated financial statements for the year ending","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1053369/000149315223024726/0001493152-23-024726-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"engagement"},{"label":"Auditor","value":"Mazers USA LLP"}],"fact_type":"auditor_change"},{"claim_id":"878853004c555caf82ad1a7f183d94e8af107952","claim":"ELITE PHARMACEUTICALS INC /NV/ dismissed Buchbinder Tunick & Company LLP as its auditor.","evidence_excerpt":"The Audit Committee also dismissed Buchbinder Tunick & Company LLP (“Buchbinder”) as the Company’s independent registered public accounting firm, effective as of July 12, 2023.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1053369/000149315223024726/0001493152-23-024726-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"dismissal"},{"label":"Auditor","value":"Buchbinder Tunick & Company LLP"},{"label":"Successor","value":"Mazers USA LLP"}],"fact_type":"auditor_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}